ANI Pharmaceuticals (ANIP) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does ANI Pharmaceuticals (ANIP) do?
ANI Pharmaceuticals Inc (ANIP) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells specialty pharmaceuticals and generic prescription medications directly to wholesalers and health systems. Commercializes niche rare disease therapies while manufacturing high-volume generic prescription drugs in domestic. It is worth $1.57B on the market and sold $1.04B over the last year.
- Market cap
- $1.57B
- P/E ratio
- 13.8×
- Annual sales
- $1.04B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 14, 2026
Brands and businesses behind ANIP
- Cortrophin Gel: An adrenocorticotropic hormone injection prescribed for autoimmune flare-ups, sold through specialty pharmacies.
- Iluvien: An intravitreal implant that releases corticosteroid to treat diabetic macular edema, earning revenue from retina specialists.
- Yutiq: A micro-insert delivering fluocinolone acetonide to treat chronic non-infectious uveitis affecting the back of the eye.
ANIP’s flags, in plain English
Each flag is a number from ANI Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Still Climbing
Sales up 33.5% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Cheap on Cash Flow
Priced at 7.7 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Heavily Shorted
18% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about ANIP
How big is ANI Pharmaceuticals?
ANI Pharmaceuticals’ market cap is $1.57B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.04B: what customers paid the company over the last year, before any costs.
What is ANIP’s P/E ratio?
ANIP’s P/E ratio is 13.8×. Investors pay about 13.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ANIP?
Lowered annual revenue targets for Cortrophin Gel reflect mounting payer pushback and restrictions across specialty pharmacy networks. That is one risk on ANI Pharmaceuticals’ card. Its first risk flag is Heavily Shorted, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From ANI Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ANIP’s filings on SEC.gov. The Margin Monkey is research, not advice.
